3 medical AI systems clear regulatory hurdles

Dave Pearson | | Health Exec | Economics
hurdles.jpg
Photo by Interactive Sports via Unsplash

The last two weeks saw market clearances granted in Europe for AI-based software focused on remote patient monitoring, prostate oncology and real-time guidance of coronary stenting.

Company announcements:

Biobeat’s AI-powered remote patient monitoring platform receives a full CE mark (May 4)

Exini Diagnostics receives CE mark clearance for AI-powered quantitative assessment of prostate-specific membrane antigen (May 3)

Abbott’s new coronary imaging platform powered by artificial intelligence launches in Europe (April 26)

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward
UnitedHealth pushes back against shareholder transparency proposal
Thousands of staff cut from federal health agencies, including CDC and VA
Nonprofit academic hospital receives criticism after running Super Bowl ad
HeartBeam raising $10M for FDA-cleared health tech with public offering

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”